Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN.

Détails

ID Serval
serval:BIB_64F8A42C7793
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN.
Périodique
Neuro-oncology
Auteur(s)
Kilday J.P., Caldarelli M., Massimi L., Chen R.H., Lee Y.Y., Liang M.L., Parkes J., Naiker T., van Veelen M.L., Michiels E., Mallucci C., Pettorini B., Meijer L., Dorfer C., Czech T., Diezi M., Schouten-van Meeteren AYN, Holm S., Gustavsson B., Benesch M., Müller H.L., Hoffmann A., Rutkowski S., Flitsch J., Escherich G., Grotzer M., Spoudeas H.A., Azquikina K., Capra M., Jiménez-Guerra R., MacDonald P., Johnston D.L., Dvir R., Constantini S., Kuo M.F., Yang S.H., Bartels U.
ISSN
1523-5866 (Electronic)
ISSN-L
1522-8517
Statut éditorial
Publié
Date de publication
01/10/2017
Peer-reviewed
Oui
Volume
19
Numéro
10
Pages
1398-1407
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: ppublish
Résumé
Craniopharyngiomas are frequent hypothalamo-pituitary tumors in children, presenting predominantly as cystic lesions. Morbidity from conventional treatment has focused attention on intracystic drug delivery, hypothesized to cause fewer clinical consequences. However, the efficacy of intracystic therapy remains unclear. We report the retrospective experiences of several global centers using intracystic interferon-alpha.
European Société Internationale d'Oncologie Pédiatrique and International Society for Pediatric Neurosurgery centers were contacted to submit a datasheet capturing pediatric patients with cystic craniopharyngiomas who had received intracystic interferon-alpha. Patient demographics, administration schedules, adverse events, and outcomes were obtained. Progression was clinical or radiological (cyst reaccumulation, novel cysts, or solid growth).
Fifty-six children (median age, 6.3 y) from 21 international centers were identified. Median follow-up from diagnosis was 5.1 years (0.3-17.7 y). Lesions were cystic (n = 22; 39%) or cystic/solid (n = 34; 61%). Previous progression was treated in 43 (77%) patients before interferon use. In such cases, further progression was delayed by intracystic interferon compared with the preceding therapy for cystic lesions (P = 0.0005). Few significant attributable side effects were reported. Progression post interferon occurred in 42 patients (median 14 mo; 0-8 y), while the estimated median time to definitive therapy post interferon was 5.8 (1.8-9.7) years.
Intracystic interferon-alpha can delay disease progression and potentially offer a protracted time to definitive surgery or radiotherapy in pediatric cystic craniopharyngioma, yet demonstrates a favorable toxicity profile compared with other therapeutic modalities-important factors for this developing age group. A prospective, randomized international clinical trial assessment is warranted.
Mots-clé
Adolescent, Child, Child, Preschool, Craniopharyngioma/metabolism, Craniopharyngioma/radiotherapy, Female, Humans, Injections, Intralesional/methods, Interferon-alpha/metabolism, Male, Pituitary Neoplasms/radiotherapy, Retrospective Studies, craniopharyngioma, intracystic interferon, pediatric, retrospective
Pubmed
Web of science
Open Access
Oui
Création de la notice
23/05/2017 18:06
Dernière modification de la notice
20/08/2019 15:21
Données d'usage